Revive Therapeutics (RVVTF) Enters the Danger Zone.
What Danger You Ask?
Danger #1, the FDA doesn't like the data, and you own the stock.
Danger #2, the FDA does like the data, and...
Ehave, Inc. Announces its KetaDASH Mobile Unit Delivered to Miami Beach.
MIAMI, June 03, 2022 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its...
Revive’s Quarterly Report, Discussion, and a Video!
With 5,000 hospitalizations reported daily (150,000 a month), contracting Covid is not something to be taken lightly - after you get it.
Unless of...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found in Virtually all...
Cybin (CYBN) and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s...
- Preliminary data confirm Flow's ability to successfully measure neuro-effect of ketamine over 10 days -
- Results to be presented at PSYCH Symposium taking...
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
As we stated earlier, Revive Therapeutics (RVVTF)...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...
Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...
New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Early Bird Gets the Worm?
Here's...
Revive Therapeutics (RVVTF, RVV): Updates and News Archive.
Recent Headlines
(See FDA Filing Submission at Bottom)
LIVE QUOTE
NEWS ARCHIVE INTRO
“These medicines have a sweet spot. If the day you get diagnosed with COVID you...
Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs
TORONTO, Jan. 17, 2022 (GLOBE...















